CleanCap® beta gal mRNA (5moU) - (L-7208)
β-galactosidase (β-gal), a protein product of the baterial LacZ gene, catalyzes the conversion of β-galactosides into monosaccharides. β-gal is a common marker gene used to assess transfection efficiency.
This mRNA is capped using CleanCap, TriLink's proprietary co-transciptional capping method, which results in the naturally occuring Cap 1 structure with high capping efficiency. It is polyadenylated, modified with 5-methoxyuridine and optimized for mammalian systems. It mimics a fully processed mature mRNA.
|Purity||Passes Agarose Gel Mobility|
|Base Composition||Fully substituted with 5-Methoxy-U|
|Buffer||1 mM Sodium Citrate pH 6.4|
|Conversion Factor||40 µg/OD260|
|Recommended Storage||At or below -40°C|
|Other Name(s)||CleanCap®Beta galactosidase mRNA (5-methoxyuridine), β-gal mRNA (5moU), b-gal mRNA (5moU), LacZ mRNA (5-methoxyuridine)|
Ask an Expert
CoA search tool
CleanCap For Research Use Only. Not for use in humans. Not for use in diagnostic or therapeutic purposes. For additional licensing restrictions, please see the license agreement at trilinkbiotech.com/cleancap-research-license. Patent or patent pending,see trilinkbiotech.com/legal-notices.
Products are for research use only, not for use in diagnostic or therapeutic procedures or for use in humans. Products are not for resale without express written permission of Seller. No license under any patent or other intellectual property right of Seller or its licensors is granted or implied by the purchase unless otherwise provided in writing.
TriLink does not warrant that the use or sale of the products delivered hereunder will not infringe the claims of any United States or other patents or patents pending covering the use of the product alone or in combination with other products or in the operation of any process. All and any use of TriLink product is the purchaser's sole responsibility.